None

GNI looks to begin Chinese trials with pirfenidone for diabetic nephropathy

The wholly owned Shanghai Genomics subsidiary of the Japan-based venture GNI has applied to begin the clinical development in China of its lead product, pirfenidone, for the additional indication of d...

Pirfenidone approved by NICE for pulmonary fibrosis

Pirfenidone (Esbriet) can now be prescribed on the NHS for some patients with idiopathic pulmonary fibrosis in England and Wales, according to new guidance from the National Institute for Health and...

Assessing The Extent Of Added Benefit From Pirfenidone

Pirfenidone inhibits the development of inflammation and scarring (fibrosis) in pulmonary tissue and has been approved for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) since t...

Increasing Treatment Of Idiopathic Pulmonary Fibrosis With Pirfenidone, European Survey Shows

Nearly half of European respiratory specialists taking part in a recent survey use pirfenidone (Esbriet®, InterMune) as first-line treatment in patients newly diagnosed with idiopathic pulmonary fibr...

Esbriet pirfenidone regulatory update

Pirespa pirfenidone regulatory update

Esbriet pirfenidone: Completed Phase III enrollment

InterMune Reports New Analyses from the RECAP Study of Esbriet (pirfenidone) at ERS

Pirfenidone suppresses keloid fibroblast-embedded collagen gel contraction.

Keloid is a clinically intractable disease that causes disfigurement, itching, and pain due to abnormal proliferation of fibroblasts and production of collagen. Pirfenidone is a novel anti-fibrotic ag...

Pirfenidone restricts Th2 differentiation in vitro and limits Th2 response in experimental liver fibrosis.

Polarized T helper type 2 (Th2) response is linked with fibrosis. Here, we evaluated the effect of the anti-fibrotic agent pirfenidone on Th type 1 (Th1) and Th2 responses. For in vivo testing; Wistar...

The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial.

ABSTRACT: BACKGROUND: Our phase III clinical trial of pirfenidone for patients with idiopathic pulmonary fibrosis (IPF) revealed the efficacy in reducing the decline of vital capacity (VC) and increas...

Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?

Currently, there are no approved pharmacological treatments for the management of patients with idiopathic pulmonary fibrosis (IPF) in the USA or Europe. Pirfenidone is an orally bio-available small m...

Pirfenidone: in idiopathic pulmonary fibrosis.

Pirfenidone is an orally administered pyridine that has orphan designation for the treatment of mild to moderate idiopathic pulmonary fibrosis (IPF) in the EU. Pirfenidone 2403 mg/day for 72 weeks a...